IDbyDNA and ARUP Labs will offer their first test for pneumonia through ARUP's established clinical network in the coming weeks.
The approach is based on a new approval of the BacT/ALERT Virtuo system and new indications for the firm's procalcitonin assay.
For the 40-target panel, the trial found an overall average weighted sensitivity and specificity of 90 and 99 percent, respectively.
The test is an improved version of one that was approved three years ago, and runs on the firm's illumigene molecular diagnostics platform.
